GET DAILY SIGNALSMaxCyte (MXCT) Delivers +49% Revenue Growth in Q3 2026
Key Takeaways
- Total revenue reached $10.2 million in the third quarter of 2026, up 49% from $6.8 million a year earlier.
- Core revenue grew 27% to $8.2 million, while Strategic Platform License (SPL) program-related revenue contributed roughly $2.0 million.
- Net loss narrowed to $4.8 million, or $0.05 per share, from $12.4 million, or $0.12 per share, in the prior-year period.
- Management raised full-year 2026 revenue guidance to at least $34.5 million and announced a definitive agreement to acquire Akron Bio.
Why This Quarter Matters
MXCT is a cell-engineering company that provides platform technologies to cell and gene therapy developers. After a difficult 2025 when annual revenue fell about 15%, the firm entered 2026 aiming to regain momentum. Its third-quarter results serve as an important checkpoint. Revenue comes from instrument sales, processing assemblies, and SPL agreements that link the company's performance to the clinical and commercial success of its partners. Because SPL-related payments can fluctuate, both core revenue and SPL contributions deserve close attention. The quarter gained additional significance when management used the release to announce the acquisition of Akron Bio, signaling both near-term progress and a longer-term strategic shift.
The Numbers Behind the Report
For the three months ended September 30, 2026, total revenue came in at $10.2 million, a 49% rise from $6.8 million in the same period of 2025. Core revenue increased 27% to $8.2 million, helped by earlier-than-expected instrument purchases from a major customer. SPL-related revenue added roughly $2.0 million in milestones and royalties. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. The net loss improved to $4.8 million, or $0.05 per share, from $12.4 million, or $0.12 per share, a year ago, reflecting higher sales and disciplined spending. Gross profit rose to $8.5 million from $5.2 million. Results exceeded Wall Street forecasts, with the $0.05 loss per share beating the consensus estimate of an $0.08 loss.
Management lifted full-year 2026 revenue guidance to at least $34.5 million, up from the prior approximate $34 million target and the earlier $30 million to $32 million range. Revenue for the first nine months of 2026 reached $27.1 million, compared with $25.7 million in the corresponding period of 2025.
Market Response and Sentiment
Shares of MXCT were trading near $1.30 ahead of the report, with analysts maintaining a "Strong Buy" rating and a 12-month average price target well above the current level. The company had already previewed a solid quarter in mid-October by disclosing preliminary revenue and raising guidance. The full results confirmed that strength, with revenue and earnings both ahead of expectations. The Akron Bio acquisition announcement provided an extra strategic catalyst. Even so, MXCT is still unprofitable and cash-flow negative, so ongoing sentiment will depend more on integration progress and the route to profitability than on any single quarter's beat.
What to Watch Going Forward
The planned acquisition of Akron Bio stands out as the key development. Management views it as a step toward becoming a broader cell-therapy manufacturing partner. Akron Bio is projected to generate about $28 million in 2026 revenue and $7 million to $8 million in EBITDA while already producing positive cash flow. On a combined basis, the companies are expected to exceed $60 million in 2026 revenue, nearly doubling the standalone figure for MXCT.
Investors will want to track the deal's closing, integration costs, any new debt, and potential dilution. Core revenue growth is now expected to run around 15% year over year in the second half of 2026. SPL activity and partner clinical updates also merit attention, particularly two pivotal trials that could lead to approvals as soon as next year. Related milestones and royalties can deliver uneven but sizable revenue, so regulatory and clinical news will remain important catalysts.
Enhancing Research with Tickeron Tools
I regularly turn to Tickeron’s AI Screener when evaluating names like MXCT alongside peers. The platform lets me apply filters for technical patterns, fundamentals, and AI-driven signals to quickly surface comparable opportunities in the cell and gene therapy space. It has become a practical part of my routine for identifying setups worth deeper review without manually sifting through dozens of charts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MXCT's Indicator enters downward trend
The Aroon Indicator for MXCT entered a downward trend on October 13, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 254 similar instances where the Aroon Indicator formed such a pattern. In 233 of the 254 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for MXCT moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 19 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MXCT as a result. In 70 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for MXCT turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 43 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MXCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
MXCT broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
MXCT moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MXCT crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +12.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where MXCT advanced for three days, in 198 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.819) is normal, around the industry mean (4.142). P/E Ratio (-3.706) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.092) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. MXCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MXCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement